ATS Dermagraft Approval Breaks Apligraf Monopoly In Chronic Wounds
This article was originally published in The Gray Sheet
Executive Summary
Advanced Tissue Sciences plans a PMA supplement supported by an ongoing 240-patient U.S. trial for expanded use of its Dermagraft tissue-engineered, living dermal substitute to treat venous ulcers. FDA approval for diabetic foot ulcers was received Sept. 28.